Anthos Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
99 High St, Boston, Massachusetts, 02110...Website
www.anthostherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Anthos Therapeutics
Anthos Therapeutics is focused on developing innovative anticoagulant therapies to address significant unmet medical needs, particularly in areas such as atrial fibrillation and cancer-associated thrombosis. The company is advancing its lead product, abelacimab, which is designed to provide effective anticoagulation with a reduced risk of bleeding. Their mission is to transform the lives of patients by improving treatment options for those at risk of thromboembolic events. Anthos Therapeutics aims to revolutionize anticoagulant therapy by targeting Factor XI, potentially changing the landscape of treatment for cardiovascular diseases.Explore more
Anthos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anthos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Anthos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Anthos Therapeutics
Anthos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Anthos Therapeutics has new funding data
Click to see if Anthos Therapeutics had a recent Job posting/layoffs
Check out if Anthos Therapeutics is spiking on competitors!
Earning: See what the market has to say on Anthos Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Anthos Therapeutics launches new products
Recommended Actions
Find VP level buyers at Anthos Therapeutics
Find 2 more new buyers
Compare Similar Companies to Anthos Therapeutics
Compare insights from companies similar to Anthos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.7M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Anthos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Anthos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Anthos Therapeutics.
Anthos Therapeutics Tech Stack
A closer look at the technologies used by Anthos Therapeutics
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Anthos Therapeutics News & Media
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75 years old compared to younger patientsAnthos Therapeutics To Be Acquired by Novartis For Up To $3.1 Billion | News & Events
Goodwin Life Sciences team advised Anthos Therapeutics in its agreement to be acquired by Novartis. Read more.Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anthos Therapeutics
Sign Up For FreeTo access detailed company insights
Anthos Therapeutics is focused on developing innovative anticoagulant therapies to address significant unmet medical needs, particularly in areas such as atrial fibrillation and cancer-associated thrombosis. The company is advancing its lead product, abelacimab, which is designed to provide effective anticoagulation with a reduced risk of bleeding.... Read More
